Activation of pruritogenic TGR5, MRGPRA3, and MRGPRC11 on colon-innervating afferents induces visceral hypersensitivity by Castro J. et al.
Activation of pruritogenic TGR5, MrgprA3, and
MrgprC11 on colon-innervating afferents
induces visceral hypersensitivity
Joel Castro, … , Nigel W. Bunnett, Stuart M. Brierley
JCI Insight. 2019;4(20):e131712. https://doi.org/10.1172/jci.insight.131712.
  
Graphical abstract
Research Article Gastroenterology Neuroscience
Find the latest version:
http://jci.me/131712/pdf
1insight.jci.org   https://doi.org/10.1172/jci.insight.131712
R E S E A R C H  A R T I C L E
Conflict of interest: NWB is a 
founding scientist of Endosome 
Therapeutics Inc. Research in NWB’s 
laboratory is supported, in part, by 
Takeda Pharmaceuticals International.
Copyright: © 2019, Castro et al. This is 
an open access article published under 
the terms of the Creative Commons 
Attribution 4.0 International License.
Submitted: July 15, 2019 
Accepted: September 11, 2019 
Published: October 17, 2019.
Reference information: JCI Insight. 
2019;4(20):e131712.  
https://doi.org/10.1172/jci.
insight.131712.
Activation of pruritogenic TGR5, 
MRGPRA3, and MRGPRC11 on  
colon-innervating afferents induces 
visceral hypersensitivity
Joel Castro,1,2,3 Andrea M. Harrington,1,2,3 TinaMarie Lieu,4 Sonia Garcia-Caraballo,1,2,3  
Jessica Maddern,1,2,3 Gudrun Schober,1,2,3 Tracey O’Donnell,1,2,3 Luke Grundy,1,2,3  
Amanda L. Lumsden,1,2,3 Paul Miller,5 Andre Ghetti,5 Martin S. Steinhoff,6,7,8 Daniel P. Poole,4,9,10 
Xinzhong Dong,11 Lin Chang,12 Nigel W. Bunnett,13,14,15 Stuart M. Brierley1,2,3
1Visceral Pain Research Group, College of Medicine and Public Health, Flinders University, Bedford Park, South Australia, 
Australia. 2Hopwood Centre for Neurobiology, Lifelong Health Theme, South Australian Health and Medical Research 
Institute (SAHMRI), North Terrace, Adelaide, South Australia, Australia. 3Centre for Nutrition and Gastrointestinal 
Diseases, Discipline of Medicine, University of Adelaide, Adelaide, South Australia, Australia. 4Monash Institute of 
Pharmaceutical Sciences, Monash University, Parkville, Victoria, Australia. 5AnaBios Corporation, San Diego, California, 
USA. 6Department of Dermatology and Dermatology Immunology Institute, Hamad Medical Corporation, Doha, Qatar. 
7Department of Dermatology, Weill Cornell Medicine-Qatar and Weill Cornell University, New York, New York, USA. 8School 
of Medicine Qatar University, Doha, Qatar. 9Australian Research Council Centre of Excellence in Convergent Bio-Nano 
Science and Technology, Monash University, Parkville, Victoria, Australia. 10Department of Anatomy and Neuroscience, 
University of Melbourne, Parkville, Victoria, Australia. 11The Solomon H. Snyder Department of Neuroscience, Center for 
Sensory Biology, School of Medicine, Howard Hughes Medical Institute, Johns Hopkins University, Baltimore, Maryland, 
USA. 12G. Oppenheimer Centre for Neurobiology of Stress and Resilience, David Geffen School of Medicine at UCLA, UCLA, 
Los Angeles, California, USA. 13Department of Pharmacology and Therapeutics, University of Melbourne, Parkville, Victoria, 
Australia. 14Department of Surgery and 15Department of Pharmacology, Columbia University, New York, New York, USA.
Introduction
Itch, like pain, is a protective mechanism necessary for survival (1). Itch induces protective scratching that 
removes harmful irritants from the skin, while pain initiates withdrawal from and avoidance of  noxious 
stimulants. Itch and pain are detected by primary sensory dorsal root ganglion (DRG) neurons that project 
from peripheral tissues into the dorsal horn (DH) of  the spinal cord, where they release transmitters that 
Itch induces scratching that removes irritants from the skin, whereas pain initiates withdrawal 
or avoidance of tissue damage. While pain arises from both the skin and viscera, we investigated 
whether pruritogenic irritant mechanisms also function within visceral pathways. We show that 
subsets of colon-innervating sensory neurons in mice express, either individually or in combination, 
the pruritogenic receptors Tgr5 and the Mas-gene–related GPCRs Mrgpra3 and Mrgprc11. Agonists 
of these receptors activated subsets of colonic sensory neurons and evoked colonic afferent 
mechanical hypersensitivity via a TRPA1-dependent mechanism. In vivo intracolonic administration 
of individual TGR5, MRGPRA3, or MRGPRC11 agonists induced pronounced visceral hypersensitivity 
to colorectal distension. Coadministration of these agonists as an “itch cocktail” augmented 
hypersensitivity to colorectal distension and changed mouse behavior. These irritant mechanisms 
were maintained and enhanced in a model of chronic visceral hypersensitivity relevant to irritable 
bowel syndrome. Neurons from human dorsal root ganglia also expressed TGR5, as well as the 
human ortholog MRGPRX1, and showed increased responsiveness to pruritogenic agonists in 
pathological states. These data support the existence of an irritant-sensing system in the colon 
that is a visceral representation of the itch pathways found in skin, thereby contributing to sensory 
disturbances accompanying common intestinal disorders.
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excite spinal neurons (2). In the skin, histamine-dependent mechanisms contribute to itch; however, several 
distinct histamine-independent itch mechanisms have also been described. One involves the Mas-gene–
related GPCR family, which includes MRGPRA3 and MRGPRC11 (2–5). Another mechanism involves 
the bile acid receptor TGR5, also known as GPR130 or GpBAR1 (6).
MRGPRA3 and MRGPRC11 are expressed by subsets of  sensory DRG neurons innervating the skin 
(7, 8). Activation of  MRGPRA3 by the antimalarial drug chloroquine (CQ) (8), or MRGPRC11 activation 
by the endogenous pruritogen, bovine adrenal medulla 8-22 peptide (BAM8-22), induces itch (3, 9). Mice 
lacking a cluster of  Mrgpr genes (Mrgpr-cluster–/–) display significant deficits in itch induced by either CQ or 
BAM8-22, but — crucially — not itch induced by histamine (8). TGR5 is also expressed by a subpopulation 
of  peptidergic DRG neurons and activation of  TGR5 by bile acids, such as deoxycholic acid (DCA) or ole-
anolic acid (OA), induces neuronal excitability and also induces itch in mice (6, 10). These effects are lost in 
Tgr5–/– mice and are exacerbated in mice overexpressing TGR5 (Tgr5-Tg), potentially explaining why pruri-
tus is observed in patients with cholestatic liver disease, where circulating bile acids are increased by 20-fold 
(6). However, it remains unclear if  both TGR5 and MRGPR mechanisms coexist within the same DRG 
neuronal populations or whether they exist in, and therefore recruit, distinct populations of  DRG neurons.
In the colon, afferent sensitization occurs via a variety of  processes (11), including histamine-depen-
dent mechanisms (12); however, other pathways are also likely involved. For example, increased fecal levels 
of  bile acids have been implicated as the cause of  diarrhea in a subset of  patients with irritable bowel 
syndrome (IBS) (13), while abdominal pain and cramping are known side-effects of  CQ treatment (14). 
Therefore, as pain arises from both the skin and viscera, we wondered whether pruritogenic irritant mecha-
nisms identified within the skin have analogous pathways within the viscera. This is important, as chronic 
abdominal pain or discomfort associated with altered bowel habits are key symptoms of  IBS, a prevalent 
functional gastrointestinal disorder affecting ~11% of  the global population (15). These symptoms signifi-
cantly affect patient quality of  life and are notoriously difficult to treat. Although the pathophysiology of  
IBS is not completely understood, hallmarks of  IBS include hypersensitivity to mechanical events within 
the intestine in the absence of  overt pathology to the intestinal mucosa, resulting in allodynia and hyper-
algesia (15). While sensitization and neuroplasticity of  colonic afferent pathways has been implicated in 
the development and maintenance of  chronic abdominal pain in IBS (15–17), the underlying mechanisms 
contributing to afferent sensitization remain incompletely understood (18). We hypothesized that MRG-
PRA3-, MRGPRC11- and TGR5-dependent mechanisms could be important mechanisms in this process.
The aim of  this study was to determine if  colonic afferents express TGR5, MRGPRC11, and MRG-
PRA3, and if  so, whether they are present in distinct or overlapping subsets of  colon-innervating DRG 
neurons. We also aimed to determine if  agonists for TGR5, MRGPRC11, and MRGPRA3 induce changes 
in colonic sensory signaling in vitro and ex vivo and whether this translated to altered visceral sensitivity 
and behavior in vivo. We determined if  such mechanisms were present, or indeed augmented, in a model 
of  chronic visceral hypersensitivity (CVH) relevant to IBS. Crucially, we aimed to translate these findings 
to humans by using colonic biopsies and DRG sensory neurons from human donors to confirm expression 
profiles and functional mechanisms.
We demonstrate that Tgr5, MrgprA3, and MrgprC11 are all expressed by colon-innervating DRG neu-
rons, in both distinct and overlapping subsets of  sensory DRG neurons, and their activation causes funda-
mental signaling changes within colonic afferent pathways in healthy and disease states. In human DRG 
neurons, TGR5 and MRGPRX1 also display both distinct and overlapping molecular and functional 
expression profiles, with increased responsiveness to pruritogens in sensitized states.
Results
Agonists for TGR5, MRGPRA3, and MRGPRC11 evoke mechanical hypersensitivity in colonic afferents. In order to deter-
mine if  pruritogenic receptors have a functional role in colonic sensory function, we made ex vivo recordings of  
colonic afferents from mice. Application of the TGR5 agonists DCA, OA, and 3-(2-chlorophenyl)-N-(4-chloro-
phenyl)-N,5-dimethyl-4-isoxazolecarboxamide (CCDC) evoked mechanical hypersensitivity in colonic afferent 
endings from healthy mice (Figure 1, A–C). Closer examination of individual afferent responses showed that 
some afferents were unaffected by TGR5 activation, whereas others displayed pronounced mechanical hyper-
sensitivity (Figure 1, A–C), suggesting that TGR5 is expressed by specific subpopulations of colonic afferents. 
Notably, the effects of CCDC were exacerbated in colonic afferents from mice overexpressing TGR5 (Tgr5-Tg, 
Figure 1D) and lost in afferents from Tgr5-null mutant (Tgr5–/–) mice (Figure 1E). As TGR5 activates transient 
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Figure 1. Agonists for TGR5 evoke mechanical hypersensitivity in colonic afferents. (A) Application of the TGR5 agonist deoxycholic acid (DCA; 100 
μM) to the colonic mucosa for 5 minutes resulted in subsequent mechanical hypersensitivity of colonic nociceptors from healthy mice (*P < 0.05, N 
= 8). Dots represent values from individual afferents before and after DCA application. Lower panel shows representative recordings from a single 
colonic afferent nerve fiber responding to a 2 g von Frey hair (vfh) before and after incubation with DCA. (B) Application of the TGR5 agonist oleanolic 
acid (OA; 100 μM for 5 minutes) also caused mechanical hypersensitivity in nociceptors from healthy mice (**P < 0.01, N = 8). (C) The potent synthet-
ic TGR5 agonist CCDC (100 μM for 5 minutes) also evoked mechanical hypersensitivity of colonic nociceptors from healthy mice (*P < 0.05, N = 7). (D) 
CCDC-induced (100 μM) mechanical hypersensitivity was enhanced in colonic nociceptors from mice overexpressing TGR5 (Tgr5-Tg, ****P < 0.0001, N 
= 10), but (E) was not observed in colonic nociceptors from Tgr5–/– mice (P > 0.05, N = 10). (F) Furthermore, CCDC-induced (100 μM) mechanical hyper-
sensitivity was not observed in colonic nociceptors from Trpa1–/– mice (P > 0.05, N = 7), suggesting a key interaction between TGR5 and TRPA1 in the 
mechanical hypersensitivity evoked by TGR5 activation. Data represent mean ± SEM. P values determined by paired t tests.
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receptor potential ankyrin 1 (TRPA1) to induce itch (10), TRPA1 mediates nociceptive responses (19, 20), and 
we have previously shown that TRPA1 is a key integrator for the induction of mechanical hypersensitivity in 
colonic afferents by a variety of mediators (21–23), we applied CCDC to colonic afferents from Trpa1–/– mice. 
Correspondingly, we found that CCDC failed to induce mechanical hypersensitivity in afferents from Trpa1–/– 
mice (Figure 1F), suggesting that a key integration between TGR5 and TRPA1 exists in colonic afferents. In 
terms of MRGPR signaling, CQ — an agonist of MRGPRA3 — also evoked mechanical hypersensitivity in 
colonic afferents from healthy mice (Figure 2A). Similarly, the MRGPRC11 agonist BAM8-22 (Figure 2B) and 
the combined MRGPRC11/MRGPRA4 agonist neuropeptide FF (NPFF) (Figure 2C) also evoked colonic 
afferent mechanical hypersensitivity. As observed with DCA, OA, and CCDC, closer examination of individ-
ual afferent responses showed that some afferents were unaffected by CQ, BAM8-22, or NPFF, whereas others 
displayed pronounced mechanical hypersensitivity (Figure 2, A–C), suggesting MRGPRA3 and MRGPRC11 
expression on specific subpopulations of colon-innervating afferents.
To determine the mechanisms by which TGR5 and Mrgpr agonists induce colonic afferent hypersen-
sitivity, we confirmed expression of  Tgr5, Mrgpra3, and Mrgprc11 mRNA using quantitative PCR (qPCR) 
and single-cell reverse transcription PCR (RT-PCR) studies of  colonic DRG neurons. Analysis of  colonic 
mucosa from healthy mice by qPCR revealed that Tgr5, Mrgpra3, and Mrgprc11 mRNA were all expressed 
in low abundance, particularly when compared with a known epithelial target such a guanylate cyclase-C 
(Gucy2c; Figure 3A). To determine if  Tgr5, MrgprA3, and MrgprC11 were expressed by colonic afferent 
DRG neurons, we performed single-cell RT-PCR from retrogradely traced colon-innervating DRG neu-
rons. We also compared expression profiles with Trpv1 and Trpa1, key channels involved in colonic afferent 
function (11, 22, 24). Of  97 individual neurons, 19% expressed Tgr5, 27% expressed MrgprA3, and 40% 
expressed MrgprC11 (Figure 3B). In comparison, Trpv1 and Trpa1 were expressed by 72% and 56% of  
colon-innervating DRG neurons, respectively (Figure 3B). These findings indicate that these pruritogenic 
receptors are expressed on sensory neurons innervating the colon, correlating well with our observation 
that subpopulations of  afferents display mechanical hypersensitivity following application of  the respective 
Figure 2. Agonists for MRGPRA3 and MRGPRC11 evoke mechanical hypersensitivity in colonic afferents. (A) Application of the MRGPRA3 agonist 
chloroquine (CQ; 10 μM for 5 minutes) resulted in subsequent mechanical hypersensitivity of colonic nociceptors from healthy mice (**P < 0.01, N = 8). 
(B) The MRGPRC11 agonist BAM8-22 (20 μM for 5 minutes) also caused mechanical hypersensitivity in nociceptors from healthy mice (*P < 0.05, N = 8). 
(C) Application of the combined MRGPRC11/MRGPRA4 agonist neuropeptide FF (NPFF; 5 μM for 5 minutes) also evoked mechanical hypersensitivity of 
colonic nociceptors from healthy mice (**P < 0.01, N = 8). Data represent mean ± SEM. P values determined by paired t tests.
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TGR5 and MRGPR agonists. Interestingly, we found that Tgr5, Mrgpra3, and MrgprC11 were expressed 
either within the same colon-innervating DRG neuron or within separate subtypes of  neurons (Figure 3C). 
For example, of  the Tgr5-expressing population of  colonic DRG neurons, 39% also expressed Mrgpra3 
and 39% Mrgprc11 (Figure 3D). Of  the Mrgpra3 expressing population, 27% coexpressed Tgr5, while 58% 
coexpressed Mrgprc11 (Figure 3E). Moreover, of  the Mrgprc11-expressing neurons, 18% coexpressed Tgr5, 
with 38% coexpressing Mrgpra3 (Figure 3F). Overall, Tgr5, Mrgpra3, and Mrgprc11 were heavily coexpressed 
with both Trpv1 (69%–90%) and Trpa1 (50%–83%; Figure 3, C–F). Therefore, Tgr5, Mrgpra3, and Mrgprc11 
Figure 3. Tgr5, Mrgprc11, and Mrgpra3 are expressed in both distinct and overlapping subpopulations of colon-innervating DRG neurons. (A) 
qPCR analysis showing low mRNA abundance for Tgr5, Mrgpra3, and Mrgprc11 in the colonic mucosa compared with a known epithelial target gucy2c 
(guanylate cyclase-C, ****P < 0.0001, N = 7; each dot represents data from an individual mouse). (B) Single-cell RT-PCR of 97 retrogradely traced 
colon-innervating DRG neurons (from N = 5 mice) reveals that subpopulations express transcripts encoding Tgr5 (19%), Mrgpra3 (27%), Mrgprc11 
(40%), Trpv1 (72%), and Trpa1 (56%). (C) Donut plot showing expression and coexpression of genes encoding Tgr5, Mrgpra3, Mrgprc11, Trpv1, and Trpa1 
in 97 individual retrogradely traced colon-innervating DRG neurons. Each color represents an individual gene with expression marked by bold shading. 
Tgr5 is represented in the outer ring, with Trpa1 in the inner ring. Individual neurons are arranged radially, such that coexpression of genes in a single 
neuron can be easily identified running from outside to inside. Some neurons express all targets, while other neurons express combinations of 
targets. (D–F) Group data showing that (D) Tgr5, (E) Mrgpra3, and (F) Mrgprc11 are expressed individually within subpopulations of colon-innervating 
DRG neurons and also coexpress together in other subpopulations. For example, of the Tgr5-expressing colon-innervating DRG neurons from healthy 
mice, 39% coexpress MrgprA3 and 39% coexpress MrgprC11. Furthermore, Tgr5, Mrgpra3, and Mrgprc11 also coexpress with Trpv1 (69%–90%) and 
Trpa1 (50%–83%). Data in A represent mean ± SEM, with P values determined by 1-way ANOVA with Tukey’s multiple comparison tests.
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Figure 4. Colon-innervating DRG neurons respond to pruritogenic agonists for TGR5, MRGPRA3, and MRGPRC11. (A) Representative Ca2+ responses to 
the application of the TRPA1 agonist allyl isothiocyanate (AITC; 100 μM), the TGR5 agonist CCDC (100 μM), and the TRPV1 agonist capsaicin (CAP; 1 μM) 
in 3 DiI-labeled DRG neurons retrogradely labeled from the mouse colon. Right panels show Fura-2 AM image of all cells within the field of view and the 
3 DiI-labeled colon-innervating DRG neurons recorded from the left panel. Scale bar: 20μm. (B–F) Representative traces of Ca2+ responses in DiI-labeled 
colon-innervating DRG neurons to sequential application of AITC (100 μM), the TGR5 agonists (B) deoxycholic acid (DCA; 100 μM), (C) taurolithocholic acid 
(TLCA; 100 μM), and (D) CCDC (100 μM), or the (E) MRGPRA3 agonist chloroquine (CQ; 10 μM) and the (F) MRGPRC11 agonist BAM8-22 (2 μM), followed by 
capsaicin (1 μM) and KCl (50 mM; not shown). DCA, TLCA, CCDC, CQ, and BAM8-22 all activated subpopulations of colon-innervating DRG neurons with 
varying functional coexpression with TRPA1 (AITC) and/or TRPV1 (capsaicin). (G) Group data showing the percentage of colon-innervating DRG neurons 
responding to DCA (61 neurons tested), TLCA (93 neurons tested), CCDC (93 neurons tested), CQ (94 neurons tested), and BAM8-22 (110 neurons tested). 
Each dot represents data from individual coverslips from a total of 6 mice. Data presented are mean ± SEM.
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are expressed by both distinct and overlapping subsets of  colon-innervating DRG neurons, the majority of  
which coexpress Trpa1, Trpv1, or both channels (Figure 3, C–F).
Agonists for TGR5, MRGPRA3, and MRGPRC11 activate multiple populations of  isolated colon-innervating 
sensory neurons. In order to confirm the results of  our single-cell RT-PCR at a functional level, and to inves-
tigate the roles of  pruritogenic irritants in activating colon-innervating DRG neurons, we measured intra-
cellular calcium ([Ca2+]i) using Fura-2 AM in response to application of  TGR5 and MRGPR agonists 
(Figure 4, A–G). In previous studies, we have shown that DCA-evoked Ca2+ transients in DRG neurons are 
generated by a TGR5-dependent process (6, 10). Here, we show in colon-innervating DRG neurons from 
healthy mice, the TGR5 agonists DCA (Figure 4B), taurolithocholic acid (TLCA; Figure 4C), and CCDC 
(Figure 4D) all caused a robust increase in [Ca2+]i in subpopulations of  colon-innervating DRG neurons. 
Overall, 21.5% ± 4.4% of  colonic DRG neurons responded to DCA, 27.1% ± 7.2% responded to TLCA, 
and  28.6% ± 3.1% responded to CCDC (Figure 4, B–D, and G). Furthermore, the MRGPRA3 agonist CQ 
activated 20.7% ± 5.1% of  colon-innervating DRG neurons (Figure 4, E and G), with the MRGPRC11 
agonist BAM8-22 activating 24.7% ± 3.8% of  neurons (Figure 4, F and G).
To further characterize these subpopulations, we quantified the proportion of  colon-innervating DRG 
neurons that responded to TGR5 (CCDC, DCA, TLCA), MRGPRA3 (CQ), or MRGPRC11 (BAM8-
22), along with TRPA1 (allyl isothiocyanate; AITC) and TRPV1 (capsaicin) agonists (Figure 4, A–F). 
Overall, 6%–11% of  colonic DRG neurons responded to the TGR5 agonists (either DCA, TLCA, or 
CCDC), AITC, and capsaicin, suggesting functional coexpression of  TGR5, TRPA1, and TRPV1 (Sup-
plemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/jci.
insight.131712DS1). Furthermore, 7%–8% of  colon-innervating DRG neurons responded to the TGR5 
agonists and AITC, but not capsaicin (suggesting coexpression of  TGR5 and TRPA1), with only about 
2%–6% of  neurons responding to the TGR5 agonists and capsaicin alone (coexpression of  TGR5 and 
TRPV1; Supplemental Figure 1). Similarly, ~9% of  colon-innervating DRG neurons responded to CQ, 
AITC, and capsaicin (MRGPRA3, TRPA1, TRPV1 coexpression), with 4% responding to CQ and AITC 
but not capsaicin, and 7% responding to CQ and capsaicin but not AITC (Supplemental Figure 1). Finally, 
~10% of  colon-innervating DRG neurons responded to BAM8-22, AITC, and capsaicin (MRGPRC11, 
TRPA1, TRPV1 coexpression), with 8% responding to BAM8-22 and AITC but not capsaicin, and 6% 
responding to BAM8-22 and capsaicin but not AITC (Supplemental Figure 1). These results support 
a functional role for TGR5, MRGPRA3, and MRGPRC11 in overlapping and distinct populations of  
TRPA1- and/or TRPV1-expressing colon-innervating DRG neurons.
In vivo intracolonic administration of  pruritogenic agonists increases signaling within the DH of  the spinal cord. 
To determine how activation and sensitization of  colonic afferents by TGR5 and MRGPR agonists results 
in altered signaling within colonic pathways in vivo, we identified activated DH neurons by phosphorylated 
MAP-kinase-ERK-1/2 immunoreactivity (pERK-IR) in response to colorectal distension (CRD) (25–32). In 
healthy vehicle-treated mice, CRD at a pressure of  40 mmHg resulted in activation of  DH neurons within the 
thoracolumbar (T10-L1) regions of  the spinal cord (Figure 5, A and B). Pretreatment of  healthy mice with the 
TGR5 agonist CCDC enhanced CRD-evoked activation of  DH neurons (Figure 5, A and B). However, intra-
colonic administration of  CCDC alone in healthy mice did not cause activation of  DH neurons within the 
spinal cord (Supplemental Figure 2). Overall, these findings indicate that intracolonic CCDC induced colonic 
afferent mechanical hypersensitivity in vivo, which translated to increased neuronal activation within the spi-
nal cord. Consistent with this action of  TGR5, intracolonic pretreatment with CCDC in mice overexpressing 
Figure 5. In vivo intracolonic administration of the TGR5 agonist CCDC enhances colorectal distension–induced signaling within the dorsal horn of 
the spinal cord. (A) Colorectal distension (CRD) at a pressure of 40 mmHg in healthy mice results in activation of dorsal horn (DH) neurons within the 
thoracolumbar (T10-L1) spinal cord, as indicated by phospho–MAP-kinase-ERK-1/2 immunoreactivity (pERK-IR, yellow arrows). pERK-IR neurons within 
the thoracolumbar DH, activated in response to 40 mmHg CRD, were predominantly located in laminae I–IV. (B) Group data showing that mice pretreated 
with intracolonic CCDC (100 μM) displayed significantly more pERK-IR DH neurons within the thoracolumbar spinal cord following 40 mmHg CRD compared 
with 40 mmHg CRD alone (*P < 0.05; dots indicate individual counts in spinal cord sections from CRD mice [N = 7] vs. CCDC + CRD mice [N = 7]). (C and D) 
Similarly, intracolonic pretreatment with CCDC in mice overexpressing TGR5 (Tgr5-Tg) increased the number of pERK-IR–activated neurons following 40 
mmHg CRD, compared with 40 mmHg CRD alone (*P < 0.05; Tgr5-Tg CRD mice [N = 4] vs. Tgr5-Tg CCDC + CRD mice [N = 4]). (E and F) In contrast, intraco-
lonic pretreatment with CCDC in Tgr5–/– mice did not result in an increase in pERK-IR–activated neurons following 40 mmHg CRD, compared with 40 mmHg 
CRD alone (P > 0.05, Tgr5–/– CRD mice [N = 4] vs.Tgr5–/– CCDC + CRD mice [N = 4]). (G and H) Trpa1–/– mice administered an intracolonic pretreatment with 
CCDC did not display increased numbers of pERK-IR neurons following 40 mmHg CRD, compared with 40 mmHg CRD alone (P > 0.05, CRD mice [N = 4] vs. 
CCDC + CRD mice [N = 4]). Data presented are mean ± SEM. P values determined by unpaired t tests (B, D, F, and H). Dots represent data from individual 
sections of spinal cord from N = 4–7 mice. Scale bars: 100μm (A, C, E, and G).
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Figure 6. In vivo intracolonic administration of TGR5, MRGPRA3, and MRGPRC11 agonists, alone or in combination, induces visceral hypersensitivity 
to colorectal distension. (A) Intracolonic administration of CCDC (100μM) resulted in significantly enhanced visceromotor responses (VMRs) to colorectal 
distension (CRD) in healthy mice, with significant increases observed across all distension pressures. (B) Group data expressed as the total AUC of the 
VMR to CRD shows significantly elevated responses following intracolonic CCDC. Each dot represents the total AUC from an individual animal. (C) Tgr5–/– 
mice administered intracolonic CCDC (100 μM) showed significantly reduced VMRs compared with Tgr5+/+ littermates administered intracolonic CCDC. (D) 
Significantly reduced total VMRs in Tgr5–/– mice administered CCDC compared with Tgr5+/+. (E) Healthy mice administered intracolonic chloroquine (CQ; 
10 μM) have significantly elevated VMRs, particularly at 40–80 mmHg distension. (F) Intracolonic CQ significantly enhanced total VMRs compared with 
vehicle. (G) Mrgpr-cluster–/– mice intracolonically administered 10 μM CQ did not show altered VMRs nor altered (H) total VMR relative to Mrgpr-clus-
ter–/– mice administered vehicle (P > 0.05). (I) Mice administered intracolonic BAM8-22 (20 μM) have significantly elevated VMRs, particularly at noxious 
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TGR5 (Tgr5-Tg) significantly increased the number of  pERK-IR neurons following CRD, compared with 
CRD plus vehicle in Tgr5-Tg mice (Figure 5, C and D). In contrast, intracolonic pretreatment with CCDC in 
Tgr5–/– mice did not alter the number of  pERK-IR neurons following CRD compared with vehicle plus CRD 
Tgr5–/– mice (Figure 5, E and F), suggesting that TGR5 does indeed mediate the effects of  CCDC. Finally, 
Trpa1–/– mice pretreated with intracolonic CCDC followed by CRD displayed no increase in the number of  
pERK-IR neurons compared with Trpa1–/– mice with vehicle plus CRD, confirming that TRPA1 is crucial for 
TGR5-mediated mechanical hypersensitivity (Figure 5, G and H). We also observed that intracolonic admin-
istration of  CQ resulted in pronounced activation of  neurons within the DH of the spinal cord, consistent 
with in vivo activation of  MRGPRA3 in colonic sensory afferent pathways (Supplemental Figure 3).
In vivo intracolonic administration of  pruritogenic agonists increases mechanically evoked responses to CRD and 
alters animal behavior. We next assessed whether TGR5- and MRGPR-induced activation of  colonic afferents 
resulted in alterations in visceral sensitivity evoked by CRD in vivo. We measured the visceromotor response 
(VMR) to increasing CRD pressures by recording electromyographic (EMG) activity from electrodes sur-
gically implanted into the abdominal muscles (30, 33–35). In healthy mice, intracolonic administration of  
CCDC significantly enhanced VMRs to CRD at all distension pressures, indicating visceral hypersensitivity 
(Figure 6, A and B, and Supplemental Figure 4). In comparison, intracolonic CCDC in Tgr5–/– mice failed 
to induce the elevated VMR to CRD observed in Tgr5+/+ mice administered intracolonic CCDC (Figure 6, 
C and D, and Supplemental Figure 4). Intracolonic administration of  the MRGPRA3 agonist CQ signifi-
cantly enhanced the VMR to CRD in healthy mice, particularly at pressures ≥ 40 mmHg (Figure 6, E and 
F, and Supplemental Figure 4). However, CQ did not alter the VMR to CRD in Mrgpr-cluster–/– mice (Figure 
6, G and H, and Supplemental Figure 4), confirming the role of  MRGPRs in the actions of  CQ in colonic 
pathways. Intracolonic administration of  the MRGPRC11 agonist BAM8-22 in healthy mice also signifi-
cantly enhanced the VMR to CRD, although this increase was most apparent at higher, noxious distension 
pressures of  ≥ 60 mmHg (Figure 6, I and J, and Supplemental Figure 4). In contrast, BAM8-22 did not 
alter the VMR to CRD in Mrgpr-cluster–/– mice (Figure 6, K and L, and Supplemental Figure 4). Notably, 
these CCDC-, CQ-, and BAM8-22–induced changes in VMR to CRD were not due to changes in colonic 
compliance (Supplemental Figure 5, A–F), suggesting that the actions observed occurred via activation of  
receptors on afferent endings. Overall, these data show that application of  the individual agonists for TGR5, 
MRGPRA3, and MRGPRC11 can each induce visceral hypersensitivity to CRD in healthy mice.
Since TGR5, MRGPRA3, and MRGPRC11 are expressed in distinct and overlapping populations of  
colon-innervating DRG neurons, we determined if  coadministration of  these agonists, as an “itch cock-
tail,” also exacerbated visceral hypersensitivity. Concurrent intracolonic administration of  CCDC, CQ, 
and BAM8-22 evoked pronounced increases in the VMR to CRD at all distension pressures and signifi-
cantly increased the total VMR (Figure 6, M and N, and Supplemental Figure 4). In contrast, Trpa1–/– mice 
intracolonically administered the itch cocktail did not show altered VMRs to CRD relative to vehicle-ad-
ministered Trpa1–/– mice (Figure 6, O and P, Supplemental Figure 4), confirming that TRPA1 contributes to 
TGR5-, MRGPRA3-, and MRGPRC11-induced mechanical hypersensitivity in colonic afferent pathways.
To determine if  concurrent activation of  TGR5, MRGPRA3, and MRGPRC11 has effects beyond 
mechanically evoked visceral sensitization, we also recorded animal behavior in response to intracolonic 
administration of  the itch cocktail. Healthy mice coadministered CCDC, CQ, and BAM8-22 covered sig-
nificantly less distance in their enclosure (Figure 7, A–C), had a slower average velocity of  travel (Figure 
7D), displayed reduced locomotor activity (Figure 7E), and displayed more grooming behavior (Figure 7F) 
compared with vehicle-administered mice. These behavioral changes were not observed when TGR5, MRG-
PRA3, or MRGPRC11 agonists were applied individually (Supplemental Figure 6), suggesting full recruit-
ment of  these irritant pathways is required to induce profound behavioral changes in these mice. Notably, 
mice intracolonically administered CCDC, CQ, or BAM8-22, either individually or in combination, did not 
distension pressures of 70–80 mmHg. (J) Intracolonic BAM8-22 significantly enhanced total VMRs compared with vehicle. (K) Mrgpr-cluster–/– mice intra-
colonically administered 20 μM BAM8-22 had unaltered VMRs and unaltered (L) total VMRs to CRD relative to Mrgpr-cluster–/– mice administered vehicle 
(P > 0.05). (M) An intracolonic itch cocktail consisting of a combination of CCDC (100 μM), BAM8-22 (20 μM), and CQ (10 μM) significantly enhanced 
VMRs in healthy mice. This hypersensitivity was evident at 40–50 mmHg, 60–70 mmHg, and 80 mmHg. (N) The itch cocktail also significantly enhanced 
the total VMR compared with vehicle. (O) Trpa1–/– mice intracolonically administered the itch cocktail did not show altered VMRs relative to vehicle-ad-
ministered Trpa1–/– mice (P > 0.05). (P) Total VMR was unchanged in Trpa1–/– mice administered the itch cocktail compared with vehicle (P > 0.05). Data 
represent mean ± SEM. P values determined by generalized estimating equations, followed by least significant difference post hoc tests (A, C, E, G, I, K, 
M, O) or by unpaired t tests (B, D, F, H, J, L, N, P). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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display increased scratching behavior (Supplemental Figure 7), suggesting that the agonists were localized to 
the colon and did not reach the systemic circulation. Overall, our results demonstrate crucial individual and 
combined roles for TGR5, MRGPRA3, and MRGPRC11 in the sensitization of  colonic afferent pathways 
and the resultant changes in spinal cord processing, responsiveness to CRD, and animal behavior.
TGR5, MRGPRA3, and MRGPRC11 also contribute to the sensitization of  colonic afferent pathways during CVH. 
In order to determine if  the roles of  TGR5, MRGPRA3, and MRGPRC11 in evoking visceral hypersensitiv-
ity extends into disease states, we used a CVH mouse model of  IBS. CVH was induced by administration of  
intracolonic trinitrobenzenesulphonic acid (TNBS), which has been shown to induce colitis (36, 37). While 
colonic inflammation spontaneously heals over a 7-day period, these mice subsequently develop chronic 
mechanical hypersensitivity of  colonic afferents in the postinflammatory state (25–27, 30, 34, 36, 38), display 
neuroplasticity within spinal cord pathways (16, 30, 31) and exhibit visceral hypersensitivity to CRD (30, 34).
Figure 7. In vivo intracolonic administration of an itch cocktail consisting of TGR5, MRGPRA3, and MRGPRC11 agonists alters animal behavior. 
Representative track paths are shown for a (A) healthy mouse intracolonically administered vehicle (saline) and for a (B) healthy mouse intracolonically 
administered an itch cocktail consisting of a combination of CCDC (100 μM), BAM8-22 (20 μM), and CQ (10 μM). Intracolonic administration of the itch 
cocktail significantly reduced (C) the total track length covered (*P < 0.05; vehicle, N = 9; itch cocktail, N = 7), (D) the average velocity of travel (*P < 
0.05; vehicle, N = 9; itch cocktail, N = 7), and (E) locomotor activity time compared with vehicle treatment (**P < 0.01; vehicle, N = 9; itch cocktail, N = 7). 
(F) Intracolonic administration of the itch cocktail also significantly increased grooming behavior compared with vehicle (*P < 0.05; vehicle, N = 9; itch 
cocktail, N = 7). Data represent mean ± SEM. Dots represent values from individual mice. P values were by unpaired t tests (C, D, E, F).
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Figure 8. TGR5, MRGPRA3, and MRGPRC11 agonists evoke mechanical hypersensitivity in colonic afferents from 
mice with chronic visceral hypersensitivity (CVH). (A) Application of the TGR5 agonist deoxycholic acid (DCA; 100 
μM) to the colonic mucosa of CVH mice induces mechanical hypersensitivity of colonic nociceptors (**P < 0.01, N = 
7). Dots represent values from individual CVH afferents before and after DCA application. Lower panels show rep-
resentative recordings from a single colonic afferent nerve fiber from a CVH mouse responding to a 2 g vfh before 
and after incubation with DCA. (B) Application of the TGR5 agonist oleanolic acid (OA; 100 μM for 5 minutes) also 
caused mechanical hypersensitivity in nociceptors from CVH mice (**P < 0.01, N = 8). (C) The TGR5 agonist CCDC 
(100 μM for 5 minutes) also evoked mechanical hypersensitivity of colonic nociceptors from CVH mice (*P < 0.05, 
N = 7). (D) Colonic nociceptors from CVH mice also displayed mechanical hypersensitivity to the application of the 
MRGPRA3 agonist chloroquine (CQ, 10 μM for 5 minutes, *P < 0.05, N = 9), (E) MRGPRC11 agonist BAM8-22 (20 μM 
for 5 minutes, **P < 0.01, N = 9), and (F) the combined MRGPRC11/MRGPRA4 agonist neuropeptide FF (NPFF; 5 μM 
for 5 minutes, **P < 0.01, N = 9 mice). Data represent Mean ± SEM. P values determined by paired t tests (A–F).
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Colonic afferents from CVH mice displayed mechanical hypersensitivity relative to afferents from healthy 
mice (Supplemental Figure 8), as described previously (25–27, 30, 34, 36, 38). Interestingly, application of  
the TGR5 agonists DCA, OA, or CCDC further amplified mechanical hypersensitivity in CVH colonic 
afferents, above their already-elevated baseline levels (Figure 8, A–C). We also observed that a subpopulation 
of  CVH afferents displayed action potential firing to application of  the TGR5 agonists in the absence of  
mechanical stimuli, which rarely occurred in healthy colonic afferents (Supplemental Figure 9). Individual 
application of  the MRGPRA3 agonist CQ, the MRGPRC11 agonist BAM8-22, or the MRGPRC11/MRG-
PRA4 agonist NPFF also further amplified mechanical hypersensitivity in CVH colonic afferents (Figure 8, 
D–F). This was also associated with action potential firing to application of  the individual Mrgpr agonists, 
Figure 9. Distinct and overlapping expression patterns for Tgr5, Mrgpra3, and Mrgprc11 in colon-innervating DRG neurons from CVH mice. (A) Sin-
gle-cell RT-PCR of 46 retrogradely traced colon-innervating DRG neurons from 4 CVH mice reveals that subpopulations express Tgr5 (20%), Mrgpra3 (39%), 
Mrgprc11 (74%), Trpv1 (65%), and Trpa1 (74%). (B) Donut plot showing expression and coexpression of genes encoding Tgr5, Mrgpra3, Mrgprc11, Trpv1, and 
Trpa1 in 46 individual retrogradely traced colon-innervating DRG neurons from CVH mice. Each color represents an individual gene, with expression marked 
by bold shading (Tgr5, outer ring; Trpa1, inner ring). Some CVH DRG neurons express all targets, while other neurons express combinations of targets. (C–E) 
Group data showing (C) Tgr5, (D) Mrgpra3, and (E) Mrgprc11 are expressed individually within subpopulations of colon-innervating DRG neurons and also 
coexpressed together in other subpopulations. For example, of the Tgr5 expressing colon-innervating DRG neurons from CVH mice, 56% coexpress Mrg-
pra3, and 33% coexpress Mrgprc11. Tgr5, Mrgpra3, and Mrgprc11 also heavily coexpress with Trpv1 and, in particular, Trpa1 in CVH states.
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which rarely occurred in healthy colonic afferents (Supplemental Figure 9). Single-cell RT-PCR from CVH 
mice showed that 20% of  colon-innervating DRG neurons expressed Tgr5, while 39% expressed Mrgpra3 
and 74% expressed Mrgprc11, with 65% expressing Trpv1 and 74% Trpa1 (Figure 9, A and B). Compared 
with healthy colon-innervating DRG neurons, this represented a significant increase in the proportion of  
Figure 10. In vivo intracolonic administra-
tion of pruritogenic agonists in CVH mice 
increases dorsal horn neuron activation in 
response to colorectal distension and alters 
animal behavior. (A) CRD at a pressure of 40 
mmHg in CVH mice results in activation of DH 
neurons within the thoracolumbar (T10-L1) 
spinal cord, as indicated by pERK-IR (yellow 
arrows). CVH mice pretreated with intracolonic 
CCDC (100 μM) display more DH neurons in 
the spinal cord following 40 mmHg CRD. Scale 
bars: 100 μm. (B) Group data showing that 
CVH mice pretreated with intracolonic CCDC 
(100 μM) displayed significantly more pERK-IR 
DH neurons within the spinal cord following 
40 mmHg CRD compared with 40 mmHg CRD 
alone (****P < 0.0001, dots indicate individual 
counts in spinal cord sections from N = 6 CVH 
CRD and N = 6 CVH CCDC+CRD). (C) Repre-
sentative track paths are shown for individual 
CVH mice administered either intracolonic 
vehicle (saline) or an itch cocktail consisting 
of a combination of CCDC (100 μM), BAM8-22 
(20 μM), and CQ (10 μM). (D–F) Intracolonic 
administration of the itch cocktail to CVH mice 
significantly reduces (D) their track length 
covered within the central area of the obser-
vation enclosure (**P < 0.01; CVH + vehicle, N 
= 9; CVH + itch cocktail, N = 7) and (E) reduces 
their distance from the walls of the enclosure 
(*P < 0.05; CVH + vehicle, N = 9; CVH + itch 
cocktail, N = 7) compared with vehicle-treated 
CVH mice. (F) Intracolonic administration of 
the itch cocktail to CVH mice also significantly 
increased grooming behavior compared with 
CVH vehicle-treated mice (*P < 0.05; CVH + 
vehicle, N = 9; CVH + itch cocktail, N = 7). Data 
represent mean ± SEM. Dots represent values 
from individual mice. P values determined by 
unpaired t tests (B, D, E, F).
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DRG neurons expressing Mrgprc11 or Trpa1 in CVH states (Supplemental Figure 10). There were also sig-
nificant changes in the coexpression profiles of  CVH colon-innervating DRG neurons (Figure 9, C–E), with 
significantly more Mrgpra3 expressing CVH DRG neurons coexpressing Mrgprc11 and Trpa1 (Supplemental 
Figure 10) and significantly fewer Mrgprc11 neurons coexpressing Trpv1 (Supplemental Figure 10).
We also found that intracolonic administration of  CCDC alone in CVH mice resulted in pERK-IR 
within DH neurons of  the spinal cord (Supplemental Figure 2). Furthermore, CVH mice pretreated with 
CCDC displayed significantly more pERK-IR DH neurons within the spinal cord following 40 mmHg 
CRD compared with CVH mice with vehicle plus CRD (Figure 10, A and B). These findings indicate 
that in vivo intracolonic CCDC activates colonic afferents and also induces mechanical hypersensitivity 
in CVH mice. In terms of  behavioral responses, CVH mice intracolonically administered the itch cock-
tail of  concurrent CCDC, CQ, and BAM8-22 displayed significantly reduced movement in terms of  the 
distance travelled within the central observational area of  the enclosure (Figure 10, C and D), a signifi-
cantly decreased distance from the walls of  the enclosure (Figure 10E), and a significantly increased time 
spent grooming (Figure 10F). However, these CVH mice did not display increased scratching behavior in 
response to the intracolonic itch cocktail (Supplemental Figure 7). Overall, our results demonstrate that 
TGR5, MRGPRA3, and MRGPRC11 each contribute to the sensitization of  colonic afferent pathways in 
CVH states. There is an increase in MRGPRC11- and TRPA1-dependent mechanisms in CVH and that 
agonists for TGR5, MRGPRA3, and MRGPRC11 profoundly alter the behavior of  CVH mice.
Human DRG neurons express TGR5 and MRGPRX1 and respond to pruritogenic agonists. To further investigate 
the translatability of  our findings, we determined the mRNA expression profiles of  TGR5 and MRGPRX1 
(the human ortholog of  murine Mrgpra3 and Mrgprc11) in human tissue and also tested the responsiveness 
of  human DRG neurons to TGR5, MRGPRX1, TRPV1, and TRPA1 agonists. Firstly, using colonic biop-
sies from 15 human healthy subjects, we found that TGR5 had low expression compared with a known 
epithelial target GUCY2C, while MRGPRX1 was absent (Figure 11A), which is consistent with our findings 
in mouse colonic mucosa (Figure 3A). qPCR of  T9-L1 whole thoracolumbar DRG from 4 human donors 
showed expression of  TGR5, with greater abundance of  MRGPRX1 and, in particular, TRPA1 and TRPV1 
(Figure 11B). Single-cell RT-PCR from 85 individual human DRG neurons, of  predominately smaller diam-
eter, demonstrated that 38% expressed TGR5, 79% expressed MRGPRX1, 92% expressed TRPV1, and 58% 
expressed TRPA1 (Figure 11, C and D). Consistent with our observations from mouse DRG, we found that 
TGR5 and MRGPRX1 were expressed in both distinct and overlapping populations of  human DRG neurons, 
which heavily coexpressed TRPV1 or TRPA1 (Figure 11D). Specifically, of  the TGR5-expressing human 
DRG neurons, 78% coexpressed MRGPRX1, 97% coexpressed TRPV1, and 56% coexpressed TRPA1 (Figure 
11E). Of the MRGPRX1-expressing population, 37% coexpressed TGR5, 99% coexpressed TRPV1, and 60% 
coexpressed TRPA1 (Figure 11F). Of the TRPV1-expressing population, 40% coexpressed TGR5, 85% coex-
pressed MRGPRX1, and 62% coexpressed TRPA1 (Figure 11G), while — of  the TRPA1-expressing popula-
tion — 31% coexpressed TGR5, 82% coexpressed MRGPRX1, and 98% coexpressed TRPV1 (Figure 11H).
Using Ca2+ imaging of dissociated and cultured human DRG neurons, we found that subpopulations of  
neurons were activated by the application of CCDC (14%; Figure 12, A, G, and H), BAM8-22 (34%; Figure 
12, B, G, and H), CQ (10%; Figure 12, C, G, and H), and NPFF (5%; Figure 12, D, G, and H), as indicated by 
robust increases in [Ca2+]i (Figure 12, A–D). Many of these neurons also responded to capsaicin (62%; Figure 
12, E, G, and H) or AITC (27%; Figure 12, F, G, and H). In order to simulate a pathological state, we tran-
siently incubated neurons in culture with inflammatory mediators (histamine, PGE II, serotonin, bradykinin) 
Figure 11. Human DRG neurons coexpress TRG5, MRGPRX1, TRPV1, and TRPA1. (A) qPCR analysis from colonic biopsies from healthy human subjects 
show low levels of mRNA expression for TGR5 and absent MRGPRX1 (human ortholog of the mouse Mrgpra3 and Mrgprc11) compared with a known 
epithelial target GUCY2C (GC-C, ****P < 0.0001, N = 15 subjects. Dots represent averaged values from each patient sample). (B) qPCR expression analysis 
of whole human thoracolumbar (TL; T9-L1) DRG from 4 human donors. Analysis reveals abundant expression of MRGPRX1, TRPV1, and TRPA1, plus 
expression of the bile acid receptor TGR5. Dots represent averaged values from each donor at each DRG level. (C) Single-cell RT-PCR analysis showing the 
percentage of individual human DRG neurons expressing the TGR5, MRGPRX1, TRPV1, and TRPA1. Data show that, of the 85 individual human thoraco-
lumbar DRG neurons examined, 38% express TGR5, 79% express MRGPRX1, 92% expressed TRPV1, with 58% expressing TRPA1. (D) Donut plot analysis 
showing coexpression profiles of 85 individual human TL DRG neurons using single-cell RT-PCR for TGR5, MRGPRX1, TRPV1, and TRPA1. (E) Of the 38% of 
human TL DRG neurons expressing TGR5, 78% coexpress MRGPRX1, 97% coexpress TRPV1, with 56% coexpressing TRPA1. (F) Of the 79% of human DRG 
neurons expressing MRGPRX1, 37% coexpress TGR5, 99% coexpress TRPV1, with 60% coexpressing TRPA1. (G) TRPV1-expressing human DRG neurons also 
express TGR5 (40%), MRGPRX1 (85%), and TRPA1 (62%). (H) TRPA1-expressing human DRG neurons also express TGR5 (31%), MRGPRX1 (82%), and TRPV1 
(98%). Data in A and B represent mean ± SEM. P values determined by 1-way ANOVA with Tukey’s multiple comparison tests (A).
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Figure 12. Human DRG neurons respond to pruritogenic agonists for TGR5, in addition to the MRGPRX1 agonists chloroquine and BAM8–22. (A–F) 
Human DRG neurons were cultured in control media, and in order to simulate a pathological state, a subset of cultures incubated with inflammatory 
mediators. This consisted of histamine (10 μM), PGE II (10 μM), serotonin (10 μM), and bradykinin (10 μM) being incubated with the neurons for 2 hours 
before Ca2+ imaging experiments commenced. Human DRG neurons from this cohort are referred to as inflammatory mediators. Grouped data of Ca2+ 
responses in control (n = 74) and inflammatory mediator (n = 44) cultured human DRG neurons to application of the (A) TGR5 agonist CCDC (100 µM), 
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for 2 hours prior to the Ca2+ imaging experiments. Human DRG neurons from these cultures displayed greater 
amplitudes of response to the application of CCDC (Figure 12, A and G), CQ (Figure 12, C and G), capsaicin 
(Figure 12, E and G), and AITC (Figure 12, F and G). Overall, 30% of neurons from the inflammatory medi-
ator cultures responded to CCDC, 9% to CQ, 30% to BAM8-22, and 11% to NPFF, with 84% responding to 
capsaicin and 30% to AITC (Figure 12I). Overall, significantly more neurons from the inflammatory mediator 
cultures responded to capsaicin than in the normal untreated cultures (Figure 12, H–K, and Supplemental 
Figure 11). Overall, these findings in human DRG neurons largely resemble our findings in mouse colon-in-
nervating DRG neurons and suggest that TGR5 and MRGPRX1 play important roles in pruritogenic signaling 
from human DRG neurons in a variety of conditions.
Discussion
IBS affects ~11% of  the global population, and therapeutic treatments are currently lacking (15). Persistent 
hypersensitivity of  sensory pathways innervating the colon is linked to the initiation, development, and 
maintenance of  chronic discomfort and abdominal pain in IBS patients (15, 16, 39). Therefore, determin-
ing the mechanisms contributing to these processes is crucial. In the current study, we show that activation 
of  TGR5, MRGPRA3, or MRGPRC11, commonly considered as itch receptors, either individually or col-
lectively cause fundamental signaling changes within colonic afferent pathways in healthy states. Crucially, 
we also show that these mechanisms persist and, in the case of  MRGPRC11, are augmented in CVH states. 
Therefore, this study provides insights on how the activation of  pruritogenic receptors initiates colonic 
hypersensitivity and, importantly, how these receptors contribute to chronic hypersensitivity. Accordingly, 
this information may afford novel therapeutic strategies by directly targeting these receptors for the treat-
ment of  chronic discomfort and abdominal pain in IBS.
In the current study, we found that mRNA for the pruritogenic receptors Tgr5, Mrgpra3, and Mrgprc11 
were all expressed in a remarkably large population (19%, 27%, and 40%, respectively) of  mouse colon-in-
nervating DRG neurons in healthy states. Correspondingly, agonists for MRGPRA3 (CQ), MRGPRC11 
(BAM8-22), and TGR5 (DCA, TLCA, CCDC) activated ~20%–35% of  isolated colon-innervating DRG 
neurons from healthy mice. Moreover, the individual agonists for MRGPRA3, MRGPRC11, or TGR5 
each induced mechanical hypersensitivity in subpopulations of  colonic afferents from healthy mice. The ex 
vivo and in vivo sensitizing effects of  CCDC were exacerbated in Tgr5-Tg–overexpressing mice and lost in 
Tgr5–/– mice, thereby confirming the role of  TGR5 in these processes. Furthermore, mechanical hypersensi-
tivity induced by either CQ or BAM8-22 was lost in Mrgpr-cluster–/– mice, confirming the roles of  MRGPRs 
in this process. In vivo activation of  either TGR5, MRGPRA3, or MRGPRC11 caused pronounced visceral 
hypersensitivity to CRD. These findings demonstrate clear and crucial individual roles for MRGPRA3, 
MRGPRC11, and TGR5 in activating colonic afferent neurons and inducing mechanical hypersensitivity.
The sensitizing effects of  TGR5, MRGPRA3, or MRGPRC11 agonists on colonic afferents likely 
occurs via neuronal mechanisms. This is because MRGPRA3 and MRGPRC11 (40) are absent from colon-
ic tissues but are expressed on mouse and human DRG neurons. While TGR5 is expressed on colonic 
afferents, it is also expressed on colonic epithelial cells and on enteric neurons (41, 42). However, we did 
not observe any changes in muscle compliance in our studies, suggesting the actions we observed were via 
direct actions on afferents rather than via secondary mechanisms. Indeed, very recent findings show that 
bile acid sensitize afferents in the proximal colon via 5-HT3–dependent mechanisms, while these actions 
are 5-HT3 independent more distally (43). Although not specifically investigated in the current study, TGR5 
activation stimulates release of  gastrin-releasing peptide (GRP) within the spinal cord (6), while MRGPR 
activation results in the release of  both GRP (44) and natriuretic polypeptide B (4) within the spinal cord 
to induce scratching (45). These mechanisms may also contribute to the transmission of  visceral irritant 
signaling from the periphery to the spinal cord and is subject to further investigation.
MRGPRX1 agonists (B) BAM8-22 (2 μM), (C) CQ (1 μM), (D) NPFF (2 μM), (E) TRPV1 agonist capsaicin (100 nM), and (F) TRPA1 agonist AITC (50 M). Two-
way ANOVA indicate responses to CQ (*P < 0.05), capsaicin (***P < 0.001), and AITC (**P < 0.01) are all significantly increased in neurons that had been 
exposed to inflammatory mediators. (G) Peak response of neurons to CCDC (**P < 0.01), CQ (****P < 0.0001), capsaicin (****P < 0.0001), and AITC (***P 
< 0.001) were all significantly increased in human DRG neurons incubated with inflammatory mediators. (H and I) Human DRG neurons from (H) control 
and (I) inflammatory mediator cultures responding to CCDC, CQ, BAM8-22, NPFF, capsaicin, and AITC. (J and K) Donut plot analysis showing the functional 
coexpression profiles as determined by Ca2+ imaging of (J) 74 individual human DRG neurons from control cultures and (K) 32 individual human DRG 
neurons from inflammatory mediator cultures in response to CCDC, CQ, BAM8-22, NPFF, capsaicin, and AITC. Data presented are mean ± SEM. P values 
determined by 2-way ANOVA and Bonferroni post hoc tests (significance indicated within panels) (A–F) or unpaired t tests (G). 
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Importantly, we show for the first time to our knowledge that MRGPRs and TGR5 are expressed 
in both distinct and overlapping populations of  neurons. Our single-cell RT-PCR analysis reveals that 
62% of  colon-innervating DRG neurons from healthy mice express at least 1 of  the Tgr5, Mrgprc11 or 
Mrgpra3 receptors. This is an important finding, as these different molecular and functional expression 
profiles would therefore allow individual, overlapping, and additive signals to occur in response to a 
variety of  pruritogenic irritants. To test this in vivo, we administered CCDC, CQ, or BAM8-22 individ-
ually to activate either TGR5, MRGPRA3, or MRGPRC11 on colonic afferents, respectively. In each 
scenario, mechanical hypersensitivity was evident in response to CRD, with CQ and CCDC evoking 
visceral hypersensitivity across a wide range of  distension pressures. In the case of  BAM8-22, visceral 
hypersensitivity to CRD was observed at more noxious distension pressures. This is consistent with 
very recent findings showing that BAM8-22 evoked elevated pain responses to CRD in healthy mice 
(40). While intracolonic administration of  the individual agonists for TGR5, MRGPRA3, and MRG-
PRC11 evoked hypersensitivity to CRD, they did not fundamentally affect spontaneous animal behav-
ior. When we administered an itch cocktail, consisting of  a combination of  CCDC, CQ, and BAM8-22, 
to concurrently activate TGR5, MRGPRA3, and MRGPRC11 on colonic afferents, this resulted in pro-
nounced mechanical hypersensitivity to CRD across a wide range of  distension pressures. Moreover, by 
recruiting the full complement of  afferents within these irritant pathways, we also observed profound 
changes in spontaneous animal behavior evoked by visceral hypersensitivity, evident by a reduction in 
locomotor activity and increased grooming.
We found that the itch cocktail–induced mechanical hypersensitivity to CRD in vivo was not evoked 
in Trpa1–/– mice. Also, we did not observe afferent hypersensitivity, nor increased numbers of  pERK-IR 
in the DH of  the spinal cord in response to CCDC and CRD in Trpa1–/– mice. These results are con-
sistent with the coupling mechanisms described in the skin, whereby TRPA1 has been identified as the 
downstream target of  TGR5 (10), and both MRGPRA3 and MRGPRC11 (9). These previous studies 
demonstrated that neither TGR5 (10), MRGPRA3, nor MRGPRC11 (9) agonists directly activate TRPA1. 
However, Trpa1–/– mice display little to no scratching in response to CQ and BAM8-22 (9). Interestingly, 
the functional coupling between MRGPRA3 and TRPA1 is attenuated by disrupting Gβγ intracellular 
signaling, while coupling between MRGPRC11 and TRPA1 requires phospholipase-C (PLC) signaling 
(9). Similarly, TGR5 also activates TRPA1 to induce itch in mice, with TGR5 activating and sensitizing 
TRPA1 via a Gβγ- and protein kinase C–mediated (PKC-mediated) mechanisms (10). Although previous 
studies identify high coexpression of  TRPV1 with MRGPRA3 and MRGPRC11 (9), as also shown in 
the current study, there appears to be little to no interaction between these targets. CQ- and BAM8-22–
evoked Ca2+ signaling and neuronal sensitization is profoundly diminished in neurons from Trpa1–/– but 
not Trpv1–/– mice (9). Although Trpv1 coexpresses with Tgr5, deletion or antagonism of  TRPV1 has no 
effect on TGR5-induced itch (10). Comparably, in the current study, although we observed Trpv1 coex-
pression in Tgr5- (78%), Mrgpra3- (69%), or Mrgprc11-expressing (90%) colon-innervating DRG neurons, 
mechanical hypersensitivity was completely lost in studies using Trpa1–/– mice. Accordingly, colonic affer-
ents, like cutaneous afferents, appear to utilize coupling between TGR5, MRGPRA3, or MRGPRC11 via 
TRPA1 in order to mediate their sensitizing actions. These findings further highlight TRPA1 as a crucial 
integrator of  sensory signals in colonic afferents by inducing mechanical hypersensitivity in response to 
bradykinin (22), TNF-α (23), and proteases (46) and now to bile acids, CQ, and BAM8-22. Conversely, 
histamine-dependent mechanisms in the colon contribute to afferent sensitization via TRPV1-dependent 
(12) and TRPV4-dependent (47) mechanisms, potentially suggesting divergent mechanisms between hista-
mine-dependent and histamine-independent afferent sensitization.
Our observations raise the question of  why functional itch receptors are found in colonic sensory path-
ways. There are several possible roles for such irritant-sensing pathways in the colon. Firstly, bile acids 
are normally present in the colonic lumen; they are secreted into the intestinal lumen during feeding, are 
absorbed in the ileum, and are modified by the colonic microbiome (48). Also, TGR5 in enteric neurons of  
the colon contributes to bile acid–dependent stimulation of  peristalsis (41). Secondly, BAM8-22 is a proteo-
lytically cleaved product of  proenkephalin A, an endogenous ligand found throughout peripheral tissues, 
including the gastrointestinal tract (49, 50). Thirdly, while a well-recognized side-effect of  the use of  CQ in 
the treatment of  malaria is itch, less-recognized symptoms of  CQ treatment include abdominal cramping 
and pain (14). Therefore, while itch induces protective scratching that removes harmful irritants from the 
skin, identification of  TGR5, MRGRPA3, and MRGRPC11 in colonic afferents may represent an analogous 
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system in the viscera. This would provide protective mechanisms for detecting harmful irritants within 
the colon and ultimately expel them from the body via activation of  sensory afferents and recruitment of  
defecatory mechanisms (41). Accordingly, increased levels of  bile acids are implicated in diarrhea-predom-
inant IBS (51). Based on our current findings, bile acids also contribute to visceral hypersensitivity and the 
development of  abdominal discomfort and pain via activation of  TGR5 expressed on colonic afferents. In 
keeping with such a role, in vivo intracolonic administration of  CCDC evoked mechanical hypersensitivity 
and increased the number of  activated neurons within the DH of  the spinal cord following CRD. Similarly, 
in vivo intracolonic CQ administration resulted in the subsequent activation of  DH neurons within the 
spinal cord and evoked mechanical hypersensitivity to CRD.
We also demonstrate that TGR5-, MRGPRA3-, and MRGPRC11-dependent mechanisms extend 
beyond sensitization of  colonic pathways in healthy states. Crucially, by using a CVH model, we show 
that colonic afferents from CVH mice display mechanical hypersensitivity compared with afferents from 
healthy mice. Application of  CCDC, CQ, or BAM8-22 further enhanced CVH afferent responses to 
mechanical stimuli, significantly increasing responses above their already-elevated levels. Thus, activation 
of  TGR5, MRGPRA3, or MRGPRC11 in CVH states can further exacerbate visceral hypersensitivity, 
leading to hyperalgesia. Correspondingly, we also show that afferents from CVH mice were more likely 
to fire action potentials in response to pruritogens and displayed increased numbers of  pERK-IR DH 
neurons in response to intracolonic CCDC application in the absence of  CRD. Notably, significantly 
more colon-innervating DRG neurons from CVH mice express Mrgprc11 and Trpa1, with a significant 
increase in the proportion of  Mrgpra3-expressing neurons now also coexpressing Mrgprc11 and Trpa1. Our 
single-cell RT-PCR analysis reveals that 83% of  colon-innervating DRG neurons from CVH mice express 
at least 1 of  the Tgr5, Mrgprc11, or Mrgpra3 receptors, compared with only in 62% in healthy states. This 
suggests alterations in the molecular and functional phenotypes of  these neuronal subpopulations in CVH 
mice, allowing more afferents to be activated by pruritogens compared with healthy states. Correspond-
ingly, we found that using an intracolonic itch cocktail of  CCDC, CQ, and BAM8-22 to concurrently 
activate TGR5, MRGPRA3, and MRGPRC11 on colonic afferents in CVH mice caused decreases in 
locomotion and increased grooming and thigmotaxis, indicative of  anxiety-like behavior. Interestingly, 
in addition to altered intestinal motility and chronic pain, IBS patients also suffer from psychiatric condi-
tions, including depression and anxiety (15).
Finally, we show that these TGR5 and MRGPR mechanisms are also present in human DRG neu-
rons. While MRGPRs have been previously detected in human DRG (7, 49), their coexpression profiles 
with TGR5, TRPA1 and TRPV1 are unclear. Although we could not specifically identify colon-inner-
vating DRG neurons in humans, we could investigate DRG at spinal levels known to innervate the colon 
(T9-L1), in order to test the concept — both molecularly and functionally — that TGR5-, MRGPRX1-, 
TRPV1-, and TRPA1-coexpressing neurons exist in human DRG. This is important, as CQ induces itch in 
humans (52), while BAM8-22 produces itch and nociceptive sensations in humans independently of  hista-
mine release (53) and TGR5 is linked to cholestatic pruritus in humans (54). As per our findings in mouse 
DRG, we found that, with single-cell RT-PCR and calcium imaging studies, TGR5 and MRGPRX1 were 
expressed in both distinct and overlapping populations of  human DRG neurons, which largely coexpressed 
TRPV1 and/or TRPA1. While there are some discrepancies in absolute percentages between Ca2+ imaging 
and single-cell RT-PCR studies, this could be attributed to translational efficiency of  mRNA to protein 
and surface expression of  the receptors at the time of  recording. By simulating a pathological state by 
incubating neurons with inflammatory mediators, significantly increased [Ca2+]i responses were observed 
in human DRG neurons to CCDC, CQ, capsaicin, and AITC compared with normal culture conditions. 
This suggests, as in our mouse studies, that these neuronal responses to pruritogenic irritants can be readily 
“tuned” to induce hypersensitive responses in pathological conditions.
Overall, our findings shed new light on the mechanisms contributing to colonic afferent hypersensitivity in 
healthy and disease-relevant states. We identify mechanisms by which MRGPRA3, MRGPRC11, and the bile 
acid receptor TGR5 contribute to the induction of  visceral hypersensitivity and altered behavior in response 
to known pruritogens. Our findings add to the recent discovery of  an endogenous mediator, 5-Oxo-eicosatet-
raenoic acid (5-oxoETE), which activates afferents via a related MRGPR, MRGPRD, to evoke visceral hyper-
sensitivity (55). Our findings demonstrate that the roles of  TGR5, MRGPRA3, and MRGPRC11 extend 
beyond itch sensation in the skin, adding to recent work demonstrating that MRGPRC11 expressed on vagal 
sensory neurons contributes to bronchoconstriction and airway hyperresponsiveness (56). Our findings also 
2 1insight.jci.org   https://doi.org/10.1172/jci.insight.131712
R E S E A R C H  A R T I C L E
demonstrate translatability of  these TGR5 and MRGPR mechanisms and their coexpression with TRPV1 
and TRPA1 to human DRG neurons. Accordingly, targeting the TGR5- and MRGPR-dependent mecha-
nisms may prove useful in treating visceral hypersensitivity associated with common intestinal disorders.
Methods
For extensive descriptions of  the methodology, please see the Supplemental Material.
Animals. Male C57BL/6J mice aged 13–17 weeks were used for studies and acquired from an in-house 
C57BL/6J breeding programme (strain no. 000664; originally purchased from The Jackson Laboratory, 
MP14) within SAHMRI’s specific and opportunistic pathogen-free animal care facility. Some experi-
ments also utilized male Tgr5–/– (6), Trpa1–/– (22), and Mrgpr-cluster–/– mice (8) or mice over expressing 
Tgr5 (Tgr5-Tg) (6) from in-house breeding colonies at SAHMRI. Tgr5–/– and Tgr5-Tg mice were gifts origi-
nally provided by Johan Auwerx and Kristina Schoonjans, Ecole Polytechnique de Lausanne (Lausanne, 
Switzerland). Mrgpr-cluster–/– mice were gifts from Xinzhong Dong (Johns Hopkins University). Trpa1–/– 
mice were gifts originally from David Corey (Harvard University, Cambridge, Massachusetts, USA).
Mouse model of  CVH. Mice were administered intracolonic TNBS and developed colitis (25–27, 36, 
38), which healed over 7 days. These mice subsequently developed chronic colonic afferent hypersen-
sitivity (25–27, 36, 38).
Ex vivo single fiber colonic nociceptor recordings. Recordings were made from healthy, CVH, or Tgr5–/–,Tgr5-Tg, 
or Trpa1–/– mice using standard protocols (25–27, 34, 38). Mechanosensitivity was determined before and after 
a 5-minute application of OA (100 μM), DCA (100 μM), CCDC (100 μM), BAM8-22 (20 μM), CQ (10 M), 
or NPFF (5 μM).
qPCR for pruritogenic receptors in mouse colonic epithelial cells. The epithelial layer was removed from the 
colon, and RNA was extracted. qPCR was performed using commercially available hydrolysis TaqMan 
probes for Tgr5, Mrgpra3, Mrgprc11, and Gucy2c (GC-C; Supplemental Table 1). Relative abundance was 
calculated using the ΔCq method (25).
Retrograde tracing to label the cell bodies of  colon-innervating afferents. Dicarbocyanine dye,1,1-dioctade-
cyl-3,3,3,3-tetramethlindocarbocyanine methanesulfonate (DiI, 2% in ethanol; Invitrogen) or cholera toxin 
subunit B conjugated to AlexaFluor-555 (CTB-555; Invitrogen) was injected at 3 sites subserosally within 
the distal colon. Animals were left to recover for 7–10 days or 4 days, respectively, to identify cell bodies 
within the DRG (25, 31, 34).
Single-cell RT-PCR of  colon-innervating DRG neurons from healthy and CVH mice. Individual retrogradely 
traced colon-innervating DRG neurons (97 from 7 healthy mice and 46 from 4 CVH mice) were picked, 
RNA was isolated, and mRNA expression was determined in each neuron for tgr5, MrgprA3, MrgprC11, 
trpv1, and trpa1 using probes indicated within the Supplemental Methods (25).
[Ca2+]i assays of  colon-innervating DRG neurons from healthy mice. Neurons were enzymatically dissociated, 
plated onto coverslips, and cultured overnight. Neurons were loaded with Fura-2 AM (2 μM), and fluores-
cence was measured at 340 nm and 380 nm excitation and 530 nm emission (10). Neurons were tested with 
DCA (100 μM), CCDC (100 μM), TLCA (100 μM), CQ (10 μM), or BAM8-22 (20 μM) and then AITC 
(100 μM), capsaicin (1 μM), and KCl (50 mM).
Visualization of  pERK neurons within the DH of  the spinal cord following CRD. C57BL/6J healthy (32), CVH 
(25–27, 30), Trpa1–/– (21, 22), Tgr5–/– (6, 41), or Tgr5-Tg (6, 41) mice were briefly anesthetized with isoflurane 
anesthetic and a 100-μl enema of either CCDC (100 μM), CQ (10 μM), or saline (vehicle) administered intra-
colonically via a catheter. Subsequently, a 4-cm balloon catheter was inserted into the perianal canal, and 40 
mmHg CRD was performed (10 seconds on, 5 second deflation, repeated 5 times). In separate experiments, 
an enema of CQ (10 μM) was applied for 5 minutes. After anesthetic overdose, mice were fixed by transcardial 
perfusion of 4% paraformaldehyde. The spinal cord was then removed and cryoprotected. Frozen sections 
were cut and incubated with monoclonal-rabbit anti-pERK (4370, Cell Signaling Technology; AB_2315112) 
and visualized with AlexaFluor-488 (A-21441, Molecular Probes, ThermoFisher Scientific) (25–27, 30–32).
In vivo VMR to CRD. Visceral sensitivity to CRD (20, 40, 50, 60, 70, and 80 mmHg, each 20-second 
durations, applied at 4-minute intervals) was assessed using abdominal electromyography (EMG) in fully 
awake healthy (30, 33, 34), Tgr5–/–, Mrgpr-cluster–/–, or Trpa1–/– mice, following intracolonic administration 
(100 μl) of  either CCDC (100 μM), CQ (10 μM), BAM8-22 (20 μM), or an intracolonic itch cocktail con-
sisting of  a combination of  CCDC (100 μM), BAM8-22 (20 μM), and CQ (10 μM). Colonic compliance 
was assessed by applying graded volumes (40–200 μl, 20-second duration) (33, 34).
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In vivo assessment of  animal behavior. Behavioral testing was evaluated using a behavioral spectrometer 
(Behavior Sequencer, Behavioral Instruments and BiObserve) (57). Healthy or CVH mice were briefly anes-
thetized with isoflurane, and a 100-μl enema of  an itch cocktail, consisting of  CCDC (100 μM), BAM8-22 
(20 μM), and CQ (10 μM), was administered intracolonically via a lubricated catheter. A 100-μl saline 
enema was used as control. Mice were individually placed in the center of  the behavioral spectrometer, and 
their behavior was filmed, tracked and evaluated, and analyzed by a computerized video tracking system 
(Viewer3, BiObserve) for a total of  20 minutes.
Human tissue. Human DRG were acquired from 5 organ donors with whole ganglia processed for down-
stream qPCR or dissociated for single-cell RT-PCR analysis or Ca2+ imaging (25, 30). Human colonic biop-
sies from 15 healthy subjects were acquired from UCLA, recruited primarily by community advertisement.
mRNA analysis of  pruritogenic targets from human tissue. RNA was extracted from colonic biopsies 
from 15 subjects and whole bilateral DRG from 4 donors. qPCR was performed using EXPRESS One-
Step Superscript qPCR Kit reagents (Invitrogen) with commercially available TaqMan probes for TGR5, 
MRGPRX1, GUCY2C, TRPA1, and TRPV1 (Supplemental Table 1). Relative abundance was estimated 
using ΔCq method (25).
Single-cell RT-PCR of  human DRG neurons. A total of  53 human DRG neurons from 4 adult organ 
donors were individually picked. Ambion Single Cell-to-CT Kit (Invitrogen) was used on an Applied 
Biosystems 7500 Real-Time PCR System, with the TaqMan primers (Supplemental Table 1) to deter-
mine mRNA expression in each neuron for TGR5, MRGPRX1 (human ortholog of  mouse Mrgpra3 and 
Mrgprc11), TRPV1, and TRPA1.
[Ca2+]i assays of  human DRG neurons in response to pruritogens. Human DRG were dissociated, and neu-
rons were plated on coverslips and cultured. Some coverslips were cultured in normal media, while others 
— in order to mimic a pathological state — were preincubated with an “inflammatory soup” containing 
10 μM each of  histamine (MilliporeSigma), PGE II (Tocris), serotonin (Tocris), and bradykinin (Milli-
poreSigma) 2 hour prior to the experiments at 37°C. For the Ca2+ imaging experiments, neurons were 
loaded with 3 μM Fluo-8 AM, and responses to CCDC (100 μM), CQ (1 μM), BAM8-22 (2 μM), NPFF 
(2 μM), capsaicin (100 nM), and AITC (50 μM) were determined.
Statistics. Data are expressed as mean ± SEM or the percentage of  neurons/afferents. Figures were pre-
pared in GraphPad Prism 8 Software. N equals the number of  animals, while n equals the number of  neu-
rons/afferents. A P value less than 0.05 was considered significant. Differences were indicated significant at 
levels of  *P < 0.05,**P < 0.01,***P < 0.001,****P < 0.0001. VMR to CRD data were statistically analyzed 
by generalized estimating equations followed by LSD post hoc test using SPSS 23.0 (IMB). All other data 
were analyzed using GraphPad Prism 8 and analyzed if  the data were normally distributed using Kolm-
ogorov-Smirnov or Shapiro-Wilk tests. These data were then analyzed using either (a) 1-way ANOVA, 
with post hoc analysis conducted by making all possible comparisons among the treatment groups with 
the Tukey’s tests; (b) 2-way ANOVA, with Bonferroni post hoc analysis conducted by making all possible 
comparisons among the treatment groups; (c) paired or (d) unpaired 2-tailed t tests; or (e) χ2 analysis. The 
specific tests used to analyze each data set is indicated within the individual figure legends.
Study approval. All animal experiments were approved and conformed to regulatory standards and 
the ARRIVE guidelines. The Animal Ethics Committees of  the SAHMRI, Flinders University, The 
University of  Adelaide, and Monash University approved all experiments involving animals. All animal 
experiments conformed to the relevant regulatory standards and the ARRIVE guidelines. All human 
tissues used for the study were obtained by legal consent from organ donors in the United States. For 
DRG studies, the DRG were acquired from 5 organ donors with ethical consent. AnaBios Corpora-
tion’s procurement network includes only US-based organ procurement organizations and hospitals. 
Policies for donor screening and consent are the ones established by the United Network for Organ 
Sharing (UNOS). Organizations supplying human tissues to AnaBios follow the standards and proce-
dures established by the US Centres for Disease Control (CDC) and are inspected biannually by the 
Department of  Health and Human Services (DHHS). Tissue distribution is governed by IRB proce-
dures and compliance with HIPAA regulations regarding patient privacy. All transfers of  donor organs 
to AnaBios are fully traceable and periodically reviewed by US federal authorities. For human colonic 
biopsies, study approval was obtained from UCLA IRBs (IRB 12-001731), and all subjects signed a 
written informed consent form prior to starting the study.
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